drugset / Trial / NCT02929797
Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
Phase 0
Unknown
72 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
A Prospective Study on the Efficacy and Safety of CD8+NKG2D+ AKT cell immunotherapy to the pancreatic cancer patients treated with adjuvant chemotherapy.
Timeline
- Start
- 2016-08
- Primary completion
- 2017-08
- Completion
- 2019-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD8+NKG2D+ AKT Cell | Cell therapy | 5e+08 unknown | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |